A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis

Trial Profile

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Voclosporin (Primary) ; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AURA; AURA-LV
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2017 Results of a 48-week complete remission (CR) subgroup analysis based on ethnicity, sex and age, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jun 2017 Results of data trough 48 week complete remission, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2017 According to an Aurinia Pharmaceuticals media release, Prof. Vladimir A. Dobronravov is clinical investigator for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top